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Abstract
Background: Since the introduction of molecular diagnostic tools such as markers for hepatitis C
and different autoimmune diseases, liver biopsy is thought to be useful mainly for staging but not
for diagnostic purposes. The aim was to review the liver biopsies for 5 years after introduction of
testing for hepatitis C, in order to evaluate what diagnostic insights – if any – remain after serologic
testing.
Methods: Retrospective review of all liver biopsies performed between 1.1.1995 and 31.12.1999
at an academic outpatient hepatology department. The diagnoses suspected in the biopsy note
were compared with the final diagnosis arrived at during a joint meeting with the responsible
clinicians and a hepatopathologist.
Results: In 365 patients, 411 diagnoses were carried out before biopsy. 84.4 % were confirmed by
biopsy but in 8.8 %, 6.8 % and 10.5 % the diagnosis was specified, changed or a diagnosis added,
respectively. Additional diagnoses of clinical relevance were unrecognized biliary obstruction and
additional alcoholic liver disease in patients with chronic hepatitis C. Liver biopsy led to change in
management for 12.1 % of patients.
Conclusion: Even in the era of advanced virological, immunological and molecular genetic testing,
liver biopsy remains a useful diagnostic tool. The yield is particularly high in marker negative
patients but also in patients with a clear-cut prebiopsy diagnosis, liver biopsy can lead to changes
in patient management.
Background
Liver biopsy has been the gold standard for diagnosing
liver disease; however, the detection of the hepatitis C vi-
rus and the development diagnostic testing [1], the de-
velopment of criteria for autoimmune hepatitis [2] as
well as the detection of novel autoantibodies [3] makes
diagnosis of many liver diseases based on virological and
serological testing much easier and precise.
We had shown in an earlier study before anti-HCV test-
ing became available that liver biopsy changed diagnosis
and management in a sizable percentage of cases [4]. The
aim of the present study was to evaluate the diagnostic
value of liver biopsy in the era of testing for hepatitis C.
To this effect, we retrospectively analyzed the 380 liver
biopsies performed between 1.1.1995 to 31.12.1999 in our
department.
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Methods
The charts of all patients who underwent percutaneous
liver biopsy in the Department between 1.1.1995 to
31.12.1999 were reviewed and pre- and postbiopsy diag-
nosis extracted. Liver biopsies were performed on an
outpatient basis either by the Menghini technique after
ultrasound examination of the liver or by direct ultra-
sound guided biopsy. The choice of the method was left
to the attending physician. To qualify for outpatient liver
biopsy prothrombin time as assessed by the Quick value
had to be above 60 %, platelets > 60'000 and there had
to be no history of excessive bleeding. Moreover, patients
with focal lesions, dilated bile ducts or signs of hepatic
decompensation were excluded.
Prebiopsy diagnosis was done based on history, physical
examination and extensive laboratory investigations.
The prebiopsy diagnosis was recorded in the biopsy note
by the physician performing the liver biopsy. More than
one diagnosis was possible per patient. Hepatitis B was
suspected when HBs and/or anti-HBc were present.
Hepatitis C was diagnosed based on a positive anti-HCV
test; in such patients HCV-RNA was also determined.
Autoimmune hepatitis was suspected when IgG were el-
evated and/or when autoantibodies (ANA, ASM, SLA,
LKM) were present. Primary biliary cirrhosis was sus-
pected in the presence of a cholestatic enzyme pattern
and positive antimitochondrial antibodies. Hemochro-
matosis was suspected when iron saturation was above
45 and 50 % in women and men, respectively and with
ferritin in the pathological range. Alcoholic liver disease
was suspected when a corresponding history was present
and/or with an AST/ALT ratio above 1 and a markedly el-
evated – glutamyl transpeptidase. Non-alcoholic steato-
hepatitis / steatosis was suspected when there was a
negative history for alcohol abuse, usually confirmed by
a third person. Wilson's disease was suspected in pa-
tients with low serum coeruloplasmin and elevated uri-
nary copper excretion. α 1-antitrypsin deficiency was
invoked when serum α 1-antitrypsin was low.
Post-biopsy diagnosis was arrived at in a common con-
ference where the biopsy and all serological tests were re-
viewed together with the hepatopathologist (AZ).
Grading and staging was done according to Batts and
Ludwig [5].
Liver and other biochemical tests were performed by
standard autoanalyzer methods in the central clinical
laboratory of the university hospital. Serum bile acids
were determined by a commercially available radioim-
munoassay. Galactose elimination capacity was deter-
mined as previously described [6,7] and the aminopyrine
breath test using 13C-dimethyl-aminopyrine instead of
the previously reported 14C-labeled compound [8].
Results are reported as median and range or mean ±
standard deviation as indicated in the text. Predictive
value of the different tests with respect to activity and
stage was performed using Statistica (Statsoft Inc., Tulsa
OK). Multiple analysis of variance was performed with
the respective module; significant differences were local-
ized by Tukey's honest significant difference test.
Results
In the period reviewed – 1.1.1995 – 31.12.1999 – liver bi-
opsy was performed on an outpatient basis in 380 pa-
tients. In three patients no material could be obtained;
another 12 liver biopsies were performed in transplanted
patients. Since most of our liver biopsies in transplanted
patients are performed on an inpatient basis these 12 bi-
opsies were not further analyzed leaving 365 biopsies as
the basis for this report.
There were 126 female and 239 male patients with a me-
dian age of 42 (range 16–75) years. The main laboratory
findings are given in table 1. Besides the diagnostic cate-
gories listed in table 1 there were four cases of Kupffer
cell siderosis, 4 cases were normal or could not be classi-
fied, 3 patients underwent staging biopsy for Hodgkin's
lymphoma, 3 cases of α 1-antitrypsin deficiency, 2 granu-
lomatous hepatitis and one each of nodular regenerative
hyperplasia and vasculitis in the context of Wegener's
granulomatosis.
There were 411 diagnoses before biopsy; 347 (84.4 %) of
which were confirmed by biopsy. In 64 cases diagnosis
was specified (36; 8.8 %), changed (28; 6.8 %) or added
(43; 10.5 %). The details of these changes in diagnoses
are compiled in table 2. There were 43 diagnoses not
considered before performing the liver biopsy added af-
ter liver biopsy (table 3). In the post-biopsy evaluation,
311 patients carried one, 50 patients two and 4 three di-
agnoses.
There were 32 (8.8 %) patients with marker negative liv-
er disease (No autoantibodies, HBs and anti-HBc nega-
tive, anti-HCV negative, iron parameters not suggesting
hemochromatosis, ALT/AST ratio + γ -GT + MCV not
suggestive of alcohol abuse). The findings in this group
are reported in table 4. The most frequent prebiopsy di-
agnoses were steatosis and unknown hepatopathy in 14
and 9 patients, respectively. The most frequent postbiop-
sy diagnosis was steatosis or alcoholic liver disease in 14
patients. Only one biopsy was reported as normal. Clini-
cally relevant diagnoses – leading to changes in manage-
ment or further diagnostic testing were found in 5
patients, namely 3 cases of obstruction and two of mark-
er negative autoimmune hepatitis.BMC Gastroenterology 2001, 1:12 http://www.biomedcentral.com/1471-230X/1/12
The different liver tests (ALT, alkaline phosphatase, γ -
GT, bilirubin, albumin, prothrombin time, serum bile ac-
ids, galactose elimination capacity and aminopyrine
breath test were analyzed for their potential to recognize
stage in the major diagnostic groups reported in table 1.
Overall, there was a marked effect of fibrosis on the liver
tests by multiple analysis of variance for all patients
(Rao's R 3.77 p < 10-6); localization of differences (Tuk-
ey's honest significance test) revealed that prothrombin
time and platelet count differentiated between stage 4
and the other stages. Only galactose elimination capacity
was able to differentiate between all stages (figure 1) but
the overlap was too large to make this clinically relevant.
Similar results were obtained when only patients with vi-
ral hepatitis (Rao's R 3.66, p < 10-6) were tested but not
for patients with alcoholic liver disease or NASH; the n in
the other groups was too small to perform analysis of
variance. None of the liver tests including ALT predicted
Table 1: Main laboratory parameters in the different diagnostic groups. Median and range are given.
Final Dx N BR ALT Alk. P. γ -GT Albumin Ferritin GEC ABT
CHC 215 11 105 69 48 39 152 5.6 0.6
3–51 12–852 26–240 6–1105 27–53 7–4404 3.3–8.8 .04–1.76
(N)ASH 68 14 72 90 119 38 311 5.7 .43
7–126 20–852 42–333 12–2930 25–48 7–4404 3.4–8.3 .03–1.23
CHB 37 14 120 71 30 37 129 5.4 .58
5–32 18–510 39–1074 7–754 27–45 86–532 3.7–6.9 .09–.84
HC 24 12 65 84 35 37 857 5.7 .55
5–55 16–224 62–142 7–260 22–50 237–3729 4.0–8.0 .15–1.76
PBC 23 11 82 171 175 36 101 5.9 .66
5–134 13–423 68–566 26–1505 32–40 10–812 3.0–8.3 .22–1.34
AIH 11 22 242 117 91 32 196 5.5 .40
5–522 22–1360 78–283 40–600 24–41 8–4013 3.0–7.1 .04–.70
CHOL 9 17 65 98 218 40 95 6.9 .51
4–25 23–293 69–274 106–1199 24–43 40–333 4.6–6.9 .42–.54
Table 2: Modification of diagnosis by liver biopsy
Pre-biopsy (n) Diagnosis changed Diagnosis specified
Steatosis / NASH (18) Cholestasis (2) Alcoholic hepatitis (3)
Chronic hepatitis (1) NASH (5)
Gran. Hepatitis (1) Alcoholic cirrhosis (1)
Steatosis (5)
Alcoholic liver disease (12) No evidence of ALD (7) Steatosis (2)
Alcoholic hepatitis (3)
Ai liver disease (11) Ruled out (1) Ai cholangiopathy (3)
Portal fibrosis (1) PBC (1)
Steatosis (1) Overlap syndrome (4)
Hemochromatosis (8) Ruled out (5) Kupffer cell siderosis (3)
Cholestasis (7) Toxic hepatitis (1) Obstruction (2)
Alcoholic hepatitis (1) Ai cholangiopathy (1)
Autoimmune hepatitis (1) PSC (1)
Cryptogenic cirrhosis (4) Portal fibrosis (1) Ai hepatitis (1)
Steatosis (1) PSC (1)
Wilson's disease (3) Ruled out (3)
Toxic hepatitis (1) Alcoholic hepatitis (1)
Ai stands for autoimmune, PSC and PBC for primary sclerosing cholangitis and primary biliary cirrhosis, respectively. Toxic hepatitis infers drug or 
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activity in the whole patient group or in the patients with
hepatitis C and/or B.
There were was one major complication in this series:
one patient had to be hospitalized because of a bile leak
and associated severe pain. Sonography performed two
weeks earlier had been normal while postbiopsy sonog-
raphy demonstrated dilated bile ducts and further work-
up showed a small ampullary carcinoma. Two other pa-
tients had to be hospitalized over night because of severe
pain after liver biopsy; in none of them was there any
signficant pathology revealed by sonography and careful
follow-up; both were discharged free of pain the next
morning.
Discussion
Our data demonstrate that liver biopsy even in this age of
advanced serological testing modified or added to diag-
nosis in a sizable percentage of cases. While this was not
clinically relevant or represented a more precise diag-
nostic label (e.g. overlap syndrome when the prebiopsy
diagnosis was primary biliary cirrhosis), it led to addi-
tional diagnoses which affected the patients clinical
management in at least 12 cases (3.3 %) to a major and in
another 41 (8.8%) in a minor fashion. The number of
changed diagnoses is similar to that reported in asymp-
tomatic patients from the Mayo clinic [9] and – surpris-
ingly – remains comparable to that others and ourselves
had reported in the pre-hepatitis C testing era [10,4].
Hepatitis C was the most common indication for liver bi-
opsy in our patient population, an experience similar to
that reported recently from France [11]. It is not surpris-
ing that diagnosis was modified most often in this dis-
ease, the finding of additional toxic damage due to
ethanol being the most frequent finding (table 3). In
spite of a thorough history and assessment of the usual
markers of alcohol abuse significant alcohol toxicity was
Table 3: Diagnoses added to a bioptically confirmed diagnosis
Confirmed diagnosis (n) Added diagnosis (n)
Hepatitis C (30) Alcoholic liver disease (17)
Steatosis (3)
NASH (2)
Iron overload (6)
Autoimmune hepatitis (1)
Granulomatous hepatitis (1)
Iron overload (5) Hepatitis C (2)
Alcoholic liver disease (2)
Steatosis (1)
PBC (3) or PSC (1) Steatosis (2)
Alcoholic liver disease (1)
Steatosis (3) Cholestasis (2)
Biliary obstruction (1)
Alcoholic liver disease (1) Chronic hepatitis C (1)
Chronic hepatitis B (1) Steatosis (1)
Table 4: Pre- and postbiopsy diagnoses in marker negative liver 
disease
Pre-biopsy diagnosis Postbiopsy diagnosis
Steatosis (14) Steatosis (9)
Cholestasis (2)
Obstruction (1)
Granulomatous hepatitis (1)
Chronic active hepatitis (1)
Unknown (9) Steatosis (2)
Autoimmune hepatitis (1)
Obstruction (1)
Granulomatous hepatitis (1)
Sepsis (1)
Nodular regenerative hyperplasia 
(1)
Vasculitis (1)
Normal (1)
Cholestasis (4) Alcoholic liver disease (1)
Obstruction (1)
PSC (2)
Alcoholic liver disease (3) Alcoholic liver disease (2)
PSC (1)
Autoimmune hepatitis (1) Autoimmune hepatitis (1)
Toxic hepatitis (1) Toxic hepatitis (1)
Figure 1
Box and whisker plot of galactose elimination capacity (GEC)
in different stages of liver disease. Staging was performed
according to Batts and Ludwig [5]. Means, standard devia-
tions and standard errors of the mean are indicated. Galac-
tose elimination capacity was the only test differing
significantly (p < 0.05) between all stages.BMC Gastroenterology 2001, 1:12 http://www.biomedcentral.com/1471-230X/1/12
discovered only in the biopsy in 17 patients (7.9 %). This
is quite a relevant finding as alcohol intake is a well
known modifier of disease progression in chronic hepa-
titis C [12]. In one case each autoimmune and granulo-
matous hepatitis were found. The prevalence of
granulomata was thus much rarer in our series (0.5 %)
than the 10 % reported recently in hepatitis C [13].
This report deals with only day-care procedures which
has been the standard in our institution for the past 20
years; this has been shown to markedly enhance patient
acceptance [11]. It could bias the findings somewhat,
however, since patients with advanced liver disease,
most patients after orthotopic liver transplantation and
patients with focal lesions were hospitalized for liver bi-
opsy and not analyzed in the present report. We had only
one major complication in this series which could have
been avoided had sonography been performed the day of
the biopsy. Thus, Lindor et al. reported that sonography
markedly reduced morbidity and hospitalization [14].
Of particular interest when investigating the diagnostic
value of liver biopsy is the marker negative patient. This
constellation was found in 8.8 % of our patients, a per-
centage similar to that recently reported by other inves-
tigators [15,16]. In the series of Daniel et al. mostly
steatosis was detected [15]; therefore, they found liver bi-
opsy only useful for staging. Our results are more resem-
bling those of Berasain and colleagues [16] where
relevant pathology other than steatosis or NASH was de-
tected in almost half of the patients. In our series there
were several unexpected diagnoses made which affected
patient management (table 4). Berasain et al. also found
HBV-DNA or HCV-RNA in 26.7 % of patients with mark-
er negative liver disease [16]; in our series we did not test
routinely for these viruses when the usual markers were
negative.
The value of liver biopsy in staging remains uncontested
[17]; in line with other investigations [18,19] we found
none of the usual liver tests to predict fibrosis or cirrho-
sis. Platelets and prothrombin time were significantly
lower in patients with stage 4 disease but the overlap was
too large to make this a clinically useful parameter; this
is in line with a recent investigation in hepatitis C where
the Bonacini score (consisting of AST/ALT ratio, platelet
count and INR) was unable to reliably predict stage [19].
The only test differing significantly between the five stag-
es was the galactose elimination capacity. This is in line
with a smaller series of patients with hepatitis C reported
by Mion and colleagues [20]; again the overlap was too
large to give this difference clinical significance, howev-
er. Besides the staging, the liver biopsy gives several
clues with respect to anticipated response to interferon
treatment [21].
To which extent markers of fibrosis such as PIIIP, colla-
gen IV and serum hyaluronate could replace the liver bi-
opsy in staging cannot be answered from our study since
none of these markers had been measured in our pa-
tients. However, good specificity and sensitivity has been
reported by several investigators, in particular for hy-
aluronate [22–24]. Recently, a combination of different
serum proteins, serum bilirubin and g-glutamyl-
transpeptidase has been reported to be useful in predict-
ing fibrosis in patients with chronic hepatitis C [25].
Conclusion
In conclusion, even with advanced serological testing un-
recognized diseases can be found in liver biopsy in a siz-
able number of patients. In the present study this was
particularly true for hepatitis C, where additional diag-
noses – in particular alcoholic liver disease – was found
in the biopsy in over half of all patients. This leads to
changes in management in about 5 % of patients. Liver
biopsy remains a useful diagnostic tool not only for stag-
ing, but also for diagnostic purposes.
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